Hee-Jin Im1, Jee Hyun Kim2, Chang-Ho Yun3, Dong Wook Kim4, Jeeyoung Oh4. 1. Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong 18450, Korea. 2. Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University School of Medicine, Seoul 07804, Korea. 3. Department of Neurology, Seoul National University Bundang Hospital, Seongnam 13620, Korea. 4. Department of Neurology, School of Medicine, Konkuk University Hospital, Konkuk University, Seoul 05030, Korea.
Abstract
BACKGROUND: Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist. METHODS: Nonanemic and drug-naive RLS patients (n = 18) and healthy controls (n = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. RESULTS: Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, p = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00-0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00-7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety. CONCLUSIONS: This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.
BACKGROUND:Restless legs syndrome (RLS) is a common sensory motor neurological disorder that is related to iron-dopamine dysregulation and immune system alteration. We aimed to assess the effects of serum hepcidin, an iron-regulating hormone, in drug-naive RLS patients compared to healthy controls and to evaluate its role in helping to predict clinical improvement after treatment with dopamine agonist. METHODS: Nonanemic and drug-naive RLS patients (n = 18) and healthy controls (n = 15) were enrolled. The serum hepcidin and iron-related values in the serum were measured upon the first visit in both groups and 12 weeks later after dopaminergic treatment in 12 patients. Information about sociodemographic characteristics, sleep-related profiles, mood and anxiety was obtained upon the first visit in all participants as well as after treatment in RLS patients. RESULTS: Serum hepcidin levels exhibited no significant differences between patients with drug-naïve RLS and healthy controls at diagnosis (7.1 ± 2.4 vs. 7.0 ± 3.2 ng/mL, p = 0.357). Decreased hepcidin levels were significantly associated with decreased RLS severity (β = 0.002, 95% CI = 0.00-0.00, p = 0.005) and improved quality of life (β = 0.002, 95% CI = 0.00-7.01, p = 0.044) in a dose-dependent manner after 12 weeks of treatment with a dopamine agonist. This association was independent of age, sex, inflammatory markers, sleep quality, insomnia, daytime sleepiness, depression and anxiety. CONCLUSIONS: This study demonstrates the role of hepcidin in evaluating the positive therapeutic response in RLS.
Entities:
Keywords:
IRLS; hepcidin; quality of life; restless legs syndrome; treatment response
Authors: Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: James R Connor; Xin-Sheng Wang; Richard P Allen; John L Beard; Jason A Wiesinger; Barbara T Felt; Christopher J Earley Journal: Brain Date: 2009-05-25 Impact factor: 13.501
Authors: Coby M M Laarakkers; Erwin T Wiegerinck; Siem Klaver; Maria Kolodziejczyk; Hendrik Gille; Andreas M Hohlbaum; Harold Tjalsma; Dorine W Swinkels Journal: PLoS One Date: 2013-10-04 Impact factor: 3.240
Authors: Giuseppe Didato; Roberta Di Giacomo; Giuseppa Jolanda Rosa; Ambra Dominese; Marco de Curtis; Paola Lanteri Journal: Int J Environ Res Public Health Date: 2020-05-22 Impact factor: 3.390
Authors: Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara Journal: Intern Emerg Med Date: 2021-12-02 Impact factor: 5.472